74 genes
Hybrid-capture panel covering key cancer-relevant genes across the most common solid tumours.
Targeted Liquid Biopsy Assay
OncoSELECT® — targeted liquid biopsy from plasma
A kit developed specifically for liquid biopsy. 74 key genes, LOD down to 0.25% VAF for SNVs and indels. From a standard 20 ng of cfDNA extracted from plasma, you obtain the full range of variants (SNVs, indels, CNVs, fusions, TERT promoter alterations and splice variants) with a clinical report within 5 days.
- 74 Genes in the panel
- 0.25% LOD for SNVs and indels
- 5 days From sample to clinical report
- > 99% Specificity across variants
About the test
Liquid biopsy for patients with solid tumours
OncoSELECT® is a hybrid-capture panel for tracking 74 key cancer-relevant genes in circulating tumour DNA (ctDNA). It was developed and optimised for liquid biopsy from blood plasma.
The solution also includes the OncoKDM® platform for complete data analysis through to a clinical report, including recommended treatment and clinical trials.
Specifications
What OncoSELECT® offers
Broad variant spectrum
SNVs, indels, CNVs, gene fusions / translocations, TERT promoter alterations and splice variants in a single panel.
20 ng cfDNA
The recommended input is 20 ng of high-quality cfDNA from plasma. Compatible with standard extraction kits (Norgen, QIAGEN, etc.).
~ 20,000× coverage
120 M paired-end reads per sample provide an average depth of 19,000–20,000×, sufficient to detect low-frequency variants.
UMI
OncoSELECT uses UMI (Unique Molecular Identifier) technology to increase the accuracy of low-frequency variant detection.
Sequencing platforms
Validated on NextSeq 550 High Output and NovaSeq 6000 (SP / S1 / S2). Validation on Element and MGI is ongoing.
Analytical performance
Verified parameters across variant types
The limit of detection (LOD) is defined as the lowest VAF at which at least 95% of replicates yield a positive result. Data from the OncoDNA validation study:
| Variant type | LOD (VAF) | Sensitivity | Specificity | Accuracy |
|---|---|---|---|---|
| SNVs | 0.25% | 96.88% | > 99% | > 99% |
| Indels | 0.25% | 96.93% | > 99% | > 99% |
| Fusions | 0.5% | 97.60% | > 99% | > 99% |
| CNVs | 1% | > 99% | > 99% | > 99% |
Example number of samples per run
- NextSeq 550 High Output 6 samples / run
- NovaSeq 6000 SP 12 samples / run
- NovaSeq 6000 S1 24 samples / run
- NovaSeq 6000 S2 48 samples / run
Workflow
From sample to report in 5 days
All preparation takes place in your own laboratory. OncoDNA supplies the kit, the analytical processing and a clinically oriented report in the OncoKDM® platform, with expert review before delivery.
- 1
cfDNA extraction
Extraction of circulating DNA from patient plasma. The recommended input for library preparation is 20 ng of high-quality cfDNA.
- 2
Library preparation
Sequencing library preparation, compatible with Twist-based protocols and automation on Opentrons Flex.
- 3
Hybrid capture
Targeted enrichment of 74 genes using the Twist Bioscience hybrid-capture protocol with uniform coverage.
- 4
Sequencing
Compatible with Illumina sequencers. Validation on Element and MGI is ongoing.
- 5
OncoKDM® report
From secondary and tertiary analysis to a clinical report in OncoKDM®.
Clinical applications
Where OncoSELECT® delivers answers
Treatment selection
Identification of actionable variants that can be targeted with available therapy, directly from plasma and without the need for a tissue biopsy.
Disease heterogeneity
A view across all metastatic sites at once, which a single tissue biopsy cannot capture.
Clinical trial eligibility
Screening patients for clinical trials based on specific variants.
Let's start
Want OncoSELECT® in your lab?
We will be happy to go through the technical requirements with you, provide training and help with kit validation and integration with Opentrons Flex.